Beyond high-dose methotrexate and brain radiotherapy: Novel targets and agents for primary CNS lymphoma

Annals of Oncology

Volumn 25, Issue 2, 2014, Pages 316-322

  Ponzoni, M ^a   Issa, S ^b   Batchelor, T T ^c   Rubenstein, J L ^d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b MIDDLEMORE HOSPITAL   (New Zealand)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

B cell receptor; Novel agents; Primary CNS lymphoma; Protein kinases; Tumor microenvironment

Indexed keywords

B LYMPHOCYTE RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 4; JANUS KINASE; METHOTREXATE; PIM KINASE; PROTEIN BCL 6; PROTEIN KINASE; STAT PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE;

BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; GENETIC ASSOCIATION; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MACROPHAGE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMORADIOTHERAPY; LYMPHOMA; METABOLISM; PATHOLOGY; PHENOTYPE;

ANTIMETABOLITES, ANTINEOPLASTIC; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMORADIOTHERAPY; HUMANS; LYMPHOMA; METHOTREXATE; PHENOTYPE; TUMOR MICROENVIRONMENT;

EID: 84893341826     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt385     Document Type: Review

References (99)

1. Barnett LB, Schwartz E. Cerebral reticulum cell sarcoma after multiple renal transplants. J Neurol Neurosurg Psychiatry 1974; 37: 966-970.
2. Benjamin I, Case ME. Primary reticulum-cell sarcoma (microglioma) of the brain with massive cardiac metastasis. Case report. J Neurosurg 1980; 53: 714-716.
3. Henry JM, Heffner RR, Jr., Dillard SH et al. Primary malignant lymphomas of the central nervous system. Cancer 1974; 34: 1293-1302.
4. Ervin T, Canellos GP. Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer 1980; 45: 1556-1557.
5. Skarin AT, Zuckerman KS, Pitman SW et al. High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood 1977; 50: 1039-1047.
6. Bokstein F, Lossos A, Lossos IS et al. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy. Leuk Lymphoma 2002; 43: 587-593.
7. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 859-863.
8. DeAngelis LM, Yahalom J, Heinemann MH et al. Primary CNS lymphoma: combined treatment with chemotherapy and radiotherapy. Neurology 1990; 40: 80-86.
9. DeAngelis LM, Yahalom J, Thaler HT et al. Combined modality therapy for primary CNS lymphoma. J Clin Oncol 1992; 10: 635-643.
10. Glass J, Gruber ML, Cher L et al. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg 1994; 81: 188-195.
11. DeAngelis LM. Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J Neurooncol 1999; 43: 249-257.
12. Schlegel U, Pels H, Oehring R et al. Neurologic sequelae of treatment of primary CNS lymphomas. J Neurooncol 1999; 43: 277-286.
13. Gabbai AA, Hochberg FH, Linggood RM et al. High-dose methotrexate for non-AIDS primary central nervous system lymphoma. Report of 13 cases. J Neurosurg 1989; 70: 190-194.
14. Cher L, Glass J, Harsh GR et al. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 1996; 46: 1757-1759.
15. Batchelor T, Carson K, O'Neill A et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003; 21: 1044-1049.
16. Villano JL, Koshy M, Shaikh H et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer 2011; 105: 1414-1418.
17. Plotkin SR, Betensky RA, Hochberg FH et al. Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res 2004; 10: 5643-5646.
18. Thiel E, Korfel A, Martus P et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010; 11: 1036-1047.
19. Shah GD, Yahalom J, Correa DD et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007; 25: 4730-4735.
20. Rubenstein JL, Treseler P, O'Brien JM. Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematol Oncol Clin North Am 2005; 19: 705-17.
21. Rubenstein JL, Combs D, Rosenberg J et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101: 466-468.
22. Rubenstein JL, Fridlyand J, Abrey L et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25: 1350-1356.
23. Rubenstein JL, Li J, Chen L et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood 2013; 121: 745-751.
24. Wieduwilt MJ, Valles F, Issa S et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res 2012; 18: 1146-1155.
25. Batchelor TT, Grossman SA, Mikkelsen T et al. Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 2011; 76: 929-930.
26. Angelov L, Doolittle ND, Kraemer DF et al. Blood-brain barrier disruption and intraarterial methotrexate-based therapy for newly diagnosed primary CNS lymphoma: a multi-institutional experience. J Clin Oncol 2009; 27: 3503-3509.
27. Rubenstein JL, Hsi ED, Johnson JL et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 2013; 31: 3061-3068.
28. Doolittle ND, Jahnke K, Belanger R et al. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma. Leuk Lymphoma 2007; 48: 1712-1720.
29. Illerhaus G, Marks R, Ihorst G et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24: 3865-3870.
30. Illerhaus G, Muller F, Feuerhake F et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008; 93: 147-148.
31. Abrey LE, Moskowitz CH, Mason WP et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003; 21: 4151-4156.
32. Pels H, Schmidt-Wolf IG, Glasmacher A et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003; 21: 4489-4495.
33. Juergens A, Pels H, Rogowski S et al. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma. Ann Neurol 2010; 67: 182-189.
34. Braaten KM, Betensky RA, de Leval L et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003; 9: 1063-1069.
35. Camilleri-Broet S, Criniere E, Broet P et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 2006; 107: 190-196.
36. Montesinos-Rongen M, Van Roost D, Schaller C et al. Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood 2004; 103: 1869-1875.
37. Jordanova ES, Riemersma SA, Philippo K et al. Hemizygous deletions in the HLA region account for loss of heterozygosity in the majority of diffuse large B-cell lymphomas of the testis and the central nervous system. Genes Chromosomes Cancer 2002; 35: 38-48.
38. Rubenstein JL, Fridlyand J, Shen A et al. Gene expression and angiotropism in primary CNS lymphoma. Blood 2006; 107: 3716-3723.
39. Tun HW, Personett D, Baskerville KA et al. Pathway analysis of primary central nervous system lymphoma. Blood 2008; 111: 3200-3210.
40. Booman M, Szuhai K, Rosenwald A et al. Genomic alterations and gene expression in primary diffuse large B-cell lymphomas of immune-privileged sites: the importance of apoptosis and immunomodulatory pathways. J Pathol 2008; 216: 209-217.
41. Campo E, Swerdlow SH, Harris NL et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019-5032.
42. Hans CP, Weisenburger DD, Greiner TC et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275-282.
43. Chang CC, Kampalath B, Schultz C et al. Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals. Arch Pathol Lab Med 2003; 127: 208-212.
44. Momota H, Narita Y, Maeshima AM et al. Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma. J Neurooncol 2010; 98: 341-348.
45. Levy O, Deangelis LM, Filippa DA et al. Bcl-6 predicts improved prognosis in primary central nervous system lymphoma. Cancer 2008; 112: 151-156.
46. Dalla-Favera R, Ye BH, Cattoretti G et al. BCL-6 in diffuse large-cell lymphomas. Important Adv Oncol 1996; 139-148. Review.
47. Cerchietti LC, Ghetu AF, Zhu X A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer Cell 2010; 17: 400-411.
48. Lopez-Girona A, Heintel D, Zhang LH et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011; 154: 325-336.
49. Zhu YX, Braggio E, Shi CX et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood 2011; 118: 4771-4779.
50. Yang Y, Shaffer AL, 3rd, Emre NC et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012; 21: 723-737.
51. Rubenstein JL, Treseler PA, Stewart PJ. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol 2011; 29: e595-e597.
52. Cox MC, Mannino G, Lionetto L et al. Lenalidomide for aggressive B-cell lymphoma involving the central nervous system?. Am J Hematol 2011; 86: 957.
53. Hernandez-Ilizaliturri FJ, Reddy N, Holkova B et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005; 11: 5984-5992.
54. Cady FM, O'Neill BP, Law ME et al. Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course. J Clin Oncol 2008; 26: 4814-4819.
55. Harada K, Nishizaki T, Kubota H et al. Distinct primary central nervous system lymphoma defined by comparative genomic hybridization and laser scanning cytometry. Cancer Genet Cytogenet 2001; 125: 147-150.
56. Boonstra R, Koning A, Mastik M et al. Analysis of chromosomal copy number changes and oncoprotein expression in primary central nervous system lymphomas: frequent loss of chromosome arm 6q. Virchows Arch 2003; 443: 164-169.
57. Schwindt H, Vater I, Kreuz M et al. Chromosomal imbalances and partial uniparental disomies in primary central nervous system lymphoma. Leukemia 2009; 23: 1875-1884.
58. Gonzalez-Aguilar A, Idbaih A, Boisselier B et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res 2012; 18: 5203-5211.
59. Courts C, Montesinos-Rongen M, Brunn A et al. Recurrent inactivation of the PRDM1 gene in primary central nervous system lymphoma. J Neuropathol Exp Neurol 2008; 67: 720-727.
60. Nakamura M, Kishi M, Sakaki T et al. Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res 2003; 63: 737-741.
61. Braggio E, McPhail ER, Macon W et al. Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens. Clin Cancer Res 2011; 17: 4245-4253.
62. Courts C, Montesinos-Rongen M, Martin-Subero JI et al. Transcriptional profiling of the nuclear factor-kappaB pathway identifies a subgroup of primary lymphoma of the central nervous system with low BCL10 expression. J Neuropathol Exp Neurol 2007; 66: 230-237.
63. Montesinos-Rongen M, Schmitz R, Brunn A Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma. Acta Neuropathol 2010; 120: 529-535.
64. Montesinos-Rongen M, Godlewska E, Brunn A et al. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathol 2011; 122: 791-792.
65. Montesinos-Rongen M, Schafer E, Siebert R et al. Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathol 2012; 124: 905-906.
66. Nagel D, Spranger S, Vincendeau M et al. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL. Cancer Cell 2012; 22: 825-837.
67. Fontan L, Yang C, Kabaleeswaran V et al. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer Cell 2012;22: 812-824.
68. Young RM, Staudt LM. A new 'brew' of MALT1 inhibitors. Cancer Cell 2012; 22: 706-707.
69. Fischer L, Hummel M, Korfel A et al. Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol 2011; 13: 1090-1098.
70. Kluk MJ, Chapuy B, Sinha P et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 2012; 7: e33813.
71. Allen JD, Verhoeven E, Domen J et al. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene 1997; 15: 1133-1141.
72. Yang Q, Chen LS, Neelapu SS et al. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood 2012; 120: 3491-3500.
73. Lin YW, Beharry ZM, Hill EG et al. A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood 2010; 115: 824-833.
74. Sasayama T, Nakamizo S, Nishihara M et al. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro Oncol 2012; 14: 368-380.
75. Rubenstein JL, Wong VS, Kadoch C et al. CXCL13 plus interleukin-10 are highly specific for the diagnosis of CNS lymphoma. Blood. 2013; 121: 4740-4748.
76. Whitcup SM, Stark-Vancs V, Wittes RE et al. Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol 1997; 115: 1157-1160.
77. Chan CC, Whitcup SM, Solomon D et al. Interleukin-10 in the vitreous of patients with primary intraocular lymphoma. Am J Ophthalmol 1995; 120: 671-673.
78. Sung CO, Kim SC, Karnan S et al. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood 2011; 117: 1291-1300.
79. Komohara Y, Horlad H, Ohnishi K et al. M2 macrophage/microglial cells induce activation of Stat3 in primary central nervous system lymphoma. J Clin Exp Hematop 2011; 51: 93-99.
80. Yang SH, Lee KS, Kim IS et al. Long-term survival in primary CNS lymphoma treated by high-dose methotrexate monochemotherapy: role of STAT6 activation as prognostic determinant. J Neurooncol 2009; 92: 65-71.
81. Ngo VN, Young RM, Schmitz R et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470: 115-119.
82. Sung KH, Lee EH, Kim YZ. Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma. J Korean Med Sci 2011; 26: 551-560.
83. He M, Zuo C, Wang J et al. Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma. Neuro Oncol. 2013; 15: 727-734.
84. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science 2011; 334: 1081-1086.
85. Wiseman RL, Balch WE. A new pharmacology-drugging stressed folding pathways. Trends Mol Med 2005; 11: 347-350.
86. Muta D, Makino K, Nakamura H et al. Inhibition of eIF4E phosphorylation reduces cell growth and proliferation in primary central nervous system lymphoma cells. J Neurooncol 2011; 101: 33-39.
87. Fischer L, Korfel A, Pfeiffer S et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res 2009; 15: 5968-5973.
88. Smith JR, Braziel RM, Paoletti S et al. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003; 101: 815-821.
89. Smith JR, Falkenhagen KM, Coupland SE et al. Malignant B cells from patients with primary central nervous system lymphoma express stromal cell-derived factor-1. Am J Clin Pathol 2007; 127: 633-641.
90. Chunsong H, Yuling H, Li W et al. CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. J Immunol 2006; 177: 6713-6722.
91. Saez de Guinoa J, Barrio L, Mellado M et al. CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics. Blood 2011; 118: 1560-1569.
92. Hoellenriegel J, Meadows SA, Sivina M et al. The phosphoinositide 30-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-3612.
93. Kawaguchi A, Orba Y, Kimura T et al. Inhibition of the SDF-1alpha-CXCR4 axis by the CXCR4 antagonist AMD3100 suppresses the migration of cultured cells from ATL patients and murine lymphoblastoid cells from HTLV-I Tax transgenic mice. Blood 2009; 114: 2961-2968.
94. Ponzoni M, Berger F, Chassagne-Clement C et al. Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. Br J Haematol 2007; 138: 316-323.
95. Bashir R, Chamberlain M, Ruby E et al. T-cell infiltration of primary CNS lymphoma. Neurology 1996; 46: 440-444.
96. Kadoch C, Dinca EB, Voicu R et al. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res 2009; 15: 1989-1997.
97. Isobe Y, Sugimoto K, Masuda A et al. Central nervous system is a sanctuary site for chronic myelogenous leukaemia treated with imatinib mesylate. Intern Med J 2009; 39: 408-411.
98. Porkka K, Koskenvesa P, Lundan T et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosomepositive leukemia. Blood 2008; 112: 1005-1012.
99. Muldoon LL, Soussain C, Jahnke K et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007; 25: 2295-2305.